Following Advisory Committee Success, Gilead Focused On Broad HCV Effort
This article was originally published in The Pink Sheet Daily
Executive Summary
Anticipating near-term U.S. and EU approvals of sofosbuvir for hepatitis C, Gilead is looking ahead to expanding the nucleoside polymerase inhibitor’s label, including a two-drug combination pill regimen for genotype 2 patients in Japan. Meanwhile, HIV drugs Stribild and Complera posted significant sales growth during the third quarter.